PT93441A - PROCESS FOR THE PREPARATION OF NEW PROTEIN-POLYMACON AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM - Google Patents

PROCESS FOR THE PREPARATION OF NEW PROTEIN-POLYMACON AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM

Info

Publication number
PT93441A
PT93441A PT93441A PT9344190A PT93441A PT 93441 A PT93441 A PT 93441A PT 93441 A PT93441 A PT 93441A PT 9344190 A PT9344190 A PT 9344190A PT 93441 A PT93441 A PT 93441A
Authority
PT
Portugal
Prior art keywords
cell
pharmaceutical compositions
compositions containing
transferrin
nucleic acids
Prior art date
Application number
PT93441A
Other languages
Portuguese (pt)
Other versions
PT93441B (en
Inventor
Hartmut Dr Beug
Max L Prof Dr Birnstiel
Matthew Dr Cotten
Ernst Dr Wagner
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of PT93441A publication Critical patent/PT93441A/en
Publication of PT93441B publication Critical patent/PT93441B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/64—General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

The invention relates to a system for the transport of nucleic acids into the cell, which takes place by receptor-mediated endocytosis. A complex can be formed with the polyanionic nucleic acid with the aid of a transferrin-polycation conjugate. This complex is bound to the transferrin receptor, of which there is high regulation in growing cells, and is absorbed into the cell. Suitable nucleic acids are those which inhibit specific genes or RNA function, such as antisense oligonucleotides or ribozymes, or the genes coding therefor. The invention further relates to a process for introducing nucleic acids into the cell, to transferrin-polycation/nucleic acid complexes and to pharmaceutical compositions containing these.
PT93441A 1989-03-16 1990-03-15 PROCESS FOR THE PREPARATION OF NEW PROTEIN-POLYMACON AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM PT93441B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AT61089 1989-03-16

Publications (2)

Publication Number Publication Date
PT93441A true PT93441A (en) 1990-11-07
PT93441B PT93441B (en) 1997-01-31

Family

ID=3495147

Family Applications (1)

Application Number Title Priority Date Filing Date
PT93441A PT93441B (en) 1989-03-16 1990-03-15 PROCESS FOR THE PREPARATION OF NEW PROTEIN-POLYMACON AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM

Country Status (20)

Country Link
US (2) US5354844A (en)
EP (1) EP0388758B1 (en)
JP (1) JP3138461B2 (en)
KR (1) KR0178022B1 (en)
AT (1) ATE195144T1 (en)
AU (1) AU637085B2 (en)
CA (1) CA2012311C (en)
DD (1) DD297842A5 (en)
DE (1) DE59010910D1 (en)
DK (1) DK0388758T3 (en)
ES (1) ES2148136T3 (en)
FI (1) FI105485B (en)
GR (1) GR3034717T3 (en)
HU (2) HU218716B (en)
IL (1) IL93755A (en)
NO (1) NO301932B1 (en)
NZ (1) NZ232918A (en)
PT (1) PT93441B (en)
RU (2) RU2098487C1 (en)
ZA (1) ZA901974B (en)

Families Citing this family (400)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5354844A (en) * 1989-03-16 1994-10-11 Boehringer Ingelheim International Gmbh Protein-polycation conjugates
US6830923B1 (en) * 1989-03-16 2004-12-14 Boehringer Inglheim International Gmbh Genetics units for inhibiting the function of RNA
EP0452457B1 (en) * 1989-11-03 1997-08-20 Vanderbilt University Method of in vivo delivery of functioning foreign genes
ES2091916T3 (en) * 1989-12-21 1996-11-16 Whitehead Biomedical Inst METHOD FOR SUPPLYING MOLECULES INSIDE EUCARIOTIC CELLS.
US6316003B1 (en) 1989-12-21 2001-11-13 Whitehead Institute For Biomedical Research Tat-derived transport polypeptides
US5804604A (en) * 1989-12-21 1998-09-08 Biogen, Inc. Tat-derived transport polypeptides and fusion proteins
US5670617A (en) * 1989-12-21 1997-09-23 Biogen Inc Nucleic acid conjugates of tat-derived transport polypeptides
EP0454044B1 (en) * 1990-04-25 1995-12-06 Hoechst Aktiengesellschaft Pharmacological product containing polyelectrolyte complexes in microparticulate form and at least one substance
WO1991017773A2 (en) * 1990-05-18 1991-11-28 Boehringer Ingelheim International Gmbh New protein-polycation conjugates
DE4110410C2 (en) * 1991-03-29 1999-05-27 Boehringer Ingelheim Int New protein-polycation conjugates
DE4104186A1 (en) * 1991-02-12 1992-08-13 Genentech Inc NEW COMPLEXES INCLUDING ENDOCYTOSIS IN HIGHER EUKARYOTIC CELLS, NUCLEIC ACID
DE4110409C2 (en) * 1991-03-29 1999-05-27 Boehringer Ingelheim Int New protein-polycation conjugates
DE4115038A1 (en) * 1991-05-08 1992-11-12 Genentech Inc NEW CONJUGATES, COMPOSED OF A GLYCOPROTEIN AND A NUCLEIC ACID-BINDING SUBSTANCE
US6030954A (en) * 1991-09-05 2000-02-29 University Of Connecticut Targeted delivery of poly- or oligonucleotides to cells
IL103059A0 (en) * 1991-09-30 1993-02-21 Boehringer Ingelheim Int Conjugates for introducing nucleic acid into higher eucaryotic cells
US5981273A (en) * 1991-09-30 1999-11-09 Boehringer Ingelheim Int'l. Gmbh Composition comprising an endosomolytic agent for introducing nucleic acid complexes into higher eucaryotic cells
RU2138553C1 (en) * 1991-09-30 1999-09-27 Берингер Ингельгейм Интернациональ ГмбХ Transfection composition for higher eucaryotic cells, nucleic acid complex useful as component of transfection composition, conjugate useful as component of transfection composition, endosomolytic peptide useful as component of transfection composition
US5521291A (en) * 1991-09-30 1996-05-28 Boehringer Ingelheim International, Gmbh Conjugates for introducing nucleic acid into higher eucaryotic cells
NZ244306A (en) * 1991-09-30 1995-07-26 Boehringer Ingelheim Int Composition for introducing nucleic acid complexes into eucaryotic cells, complex containing nucleic acid and endosomolytic agent, peptide with endosomolytic domain and nucleic acid binding domain and preparation
DE4139001A1 (en) * 1991-11-27 1993-06-03 Boehringer Mannheim Gmbh PROCESS FOR INJECTION OF NUCLEAR ACIDS IN CELLS
AU675058B2 (en) * 1991-12-23 1997-01-23 Boehringer Ingelheim International Gmbh peuroblastoma-associated regulator gene
US5922859A (en) * 1992-02-01 1999-07-13 Boehringer Ingelheim International Gmbh Complexes containing nucleic acid which can be taken-up by endocytosis into higher eukaryotic cells
AU682308C (en) * 1992-04-03 2006-08-17 Regents Of The University Of California, The Self-assembling polynucleotide delivery system
US5656609A (en) * 1992-09-24 1997-08-12 University Of Connecticut Method of enhancing and/or prolonging expression of gene introduced into a cell using colchicine
DE4311651A1 (en) * 1993-04-08 1994-10-13 Boehringer Ingelheim Int Virus for the transport of foreign DNA into higher eukaryotic cells
WO1994023751A1 (en) * 1993-04-14 1994-10-27 Boehringer Mannheim Gmbh Nucleic acid tranfer peptides and their use for injecting nucleic acids into eucaryotic cells
US6106824A (en) * 1993-08-13 2000-08-22 The Rockefeller University Expression of growth associated protein B-50/GAP-43 in vitro and in vivo
RU2025487C1 (en) * 1993-10-18 1994-12-30 Товарищество с ограниченной ответственностью "БиоПрогресс" Method for target-oriented hygienic transformation of animal's mammary gland and device for administering genetic material into animal's mammary gland lactiferous duct
US20030036056A1 (en) * 1994-01-24 2003-02-20 John J. Rossi Inhibitors and target molecule co-localization
FR2715847B1 (en) * 1994-02-08 1996-04-12 Rhone Poulenc Rorer Sa Composition containing nucleic acids, preparation and uses.
JPH10501681A (en) * 1994-02-22 1998-02-17 ダナ−ファーバー キャンサー インスティチュート Nucleic acid delivery systems and methods for their synthesis and use
US6037329A (en) * 1994-03-15 2000-03-14 Selective Genetics, Inc. Compositions containing nucleic acids and ligands for therapeutic treatment
US6551618B2 (en) 1994-03-15 2003-04-22 University Of Birmingham Compositions and methods for delivery of agents for neuronal regeneration and survival
US6077835A (en) * 1994-03-23 2000-06-20 Case Western Reserve University Delivery of compacted nucleic acid to cells
CA2186118C (en) * 1994-03-23 2010-10-19 Richard W. Hanson Compacted nucleic acids and their delivery to cells
US5844107A (en) * 1994-03-23 1998-12-01 Case Western Reserve University Compacted nucleic acids and their delivery to cells
US5972901A (en) 1994-03-23 1999-10-26 Case Western Reserve University Serpin enzyme complex receptor--mediated gene transfer
US5670347A (en) * 1994-05-11 1997-09-23 Amba Biosciences Llc Peptide-mediated gene transfer
EP0767840A2 (en) 1994-05-30 1997-04-16 BOEHRINGER INGELHEIM INTERNATIONAL GmbH Method for introducing foreign matter into higher eukaryotic cells
DE4418965A1 (en) * 1994-05-31 1995-12-07 Boehringer Ingelheim Int Transfection of eukaryotic cells with nucleic acid
WO1996000295A1 (en) * 1994-06-27 1996-01-04 The Johns Hopkins University Targeted gene delivery system
US5728399A (en) * 1994-06-29 1998-03-17 University Of Conn. Use of a bacterial component to enhance targeted delivery of polynucleotides to cells
US6471956B1 (en) 1994-08-17 2002-10-29 The Rockefeller University Ob polypeptides, modified forms and compositions thereto
US6124439A (en) * 1994-08-17 2000-09-26 The Rockefeller University OB polypeptide antibodies and method of making
US6048837A (en) * 1994-08-17 2000-04-11 The Rockefeller University OB polypeptides as modulators of body weight
US6350730B1 (en) 1994-08-17 2002-02-26 The Rockefeller University OB polypeptides and modified forms as modulators of body weight
US6124448A (en) * 1994-08-17 2000-09-26 The Rockfeller University Nucleic acid primers and probes for the mammalian OB gene
US6001968A (en) 1994-08-17 1999-12-14 The Rockefeller University OB polypeptides, modified forms and compositions
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
US6962686B2 (en) 1994-10-12 2005-11-08 California Institute Of Technology Cell-specific gene delivery vehicles
US6232295B1 (en) 1994-10-12 2001-05-15 Jon Faiz Kayyem Cell-specific contrast agent and gene delivery vehicles
GB9422495D0 (en) * 1994-11-08 1995-01-04 Medical Res Council DNA transfer method
US6221959B1 (en) 1994-11-18 2001-04-24 Supratek Pharma, Inc. Polynucleotide compositions
AU4690596A (en) * 1994-12-30 1996-07-24 Chiron Viagene, Inc. Nucleic acid condensing agents with reduced immunogenicity
US5795587A (en) 1995-01-23 1998-08-18 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
CA2212682A1 (en) 1995-02-10 1996-08-15 Worcester Foundation For Experimental Biology, Inc. Delivery of exogenous compounds
FR2730637B1 (en) * 1995-02-17 1997-03-28 Rhone Poulenc Rorer Sa PHARMACEUTICAL COMPOSITION CONTAINING NUCLEIC ACIDS, AND USES THEREOF
US6420549B1 (en) 1995-06-06 2002-07-16 Isis Pharmaceuticals, Inc. Oligonucleotide analogs having modified dimers
WO1996040961A1 (en) * 1995-06-07 1996-12-19 Life Technologies, Inc. Peptide-enhanced cationic lipid transfections
US6051429A (en) * 1995-06-07 2000-04-18 Life Technologies, Inc. Peptide-enhanced cationic lipid transfections
US5646034A (en) * 1995-06-07 1997-07-08 Mamounas; Michael Increasing rAAV titer
US20030069173A1 (en) * 1998-03-16 2003-04-10 Life Technologies, Inc. Peptide-enhanced transfections
US6127116A (en) * 1995-08-29 2000-10-03 Washington University Functional DNA clone for hepatitis C virus (HCV) and uses thereof
US5744326A (en) * 1996-03-11 1998-04-28 The Immune Response Corporation Use of viral CIS-acting post-transcriptional regulatory sequences to increase expression of intronless genes containing near-consensus splice sites
EP0904373A1 (en) * 1996-03-14 1999-03-31 The Immune Response Corporation Targeted delivery of genes encoding interferon
US5898031A (en) 1996-06-06 1999-04-27 Isis Pharmaceuticals, Inc. Oligoribonucleotides for cleaving RNA
US7812149B2 (en) 1996-06-06 2010-10-12 Isis Pharmaceuticals, Inc. 2′-Fluoro substituted oligomeric compounds and compositions for use in gene modulations
US9096636B2 (en) 1996-06-06 2015-08-04 Isis Pharmaceuticals, Inc. Chimeric oligomeric compounds and their use in gene modulation
US5679559A (en) * 1996-07-03 1997-10-21 University Of Utah Research Foundation Cationic polymer and lipoprotein-containing system for gene delivery
CN1181422A (en) * 1996-10-31 1998-05-13 上海市肿瘤研究所 Gene transfer carrier structured by polypeptide in conjunction with growth factor receptor
US6387700B1 (en) * 1996-11-04 2002-05-14 The Reagents Of The University Of Michigan Cationic peptides, Cys-Trp-(LYS)n, for gene delivery
US5965441A (en) * 1996-11-13 1999-10-12 The General Hospital Coporation HSV/AAV hybrid amplicon vectors
FR2755976B1 (en) * 1996-11-15 1999-01-15 Idm Immuno Designed Molecules NOVEL COMPLEXES OF NUCLEIC ACIDS AND POLYMER SUBSTITUTED BY RESIDUES CAUSING THE DESTABILIZATION OF CELL MEMBRANES
US7008776B1 (en) 1996-12-06 2006-03-07 Aventis Pharmaceuticals Inc. Compositions and methods for effecting the levels of high density lipoprotein (HDL) cholesterol and apolipoprotein AI very low density lipoprotein (VLDL) cholesterol and low density lipoprotein (LDL) cholesterol
US6153596A (en) * 1996-12-18 2000-11-28 Emory University Polycationic oligomers
US5969102A (en) 1997-03-03 1999-10-19 St. Jude Children's Research Hospital Lymphocyte surface receptor that binds CAML, nucleic acids encoding the same and methods of use thereof
US7049428B1 (en) 1998-03-04 2006-05-23 Washington University HCV variants
US7338759B1 (en) 1997-03-04 2008-03-04 Washington University HCV variants
AU753781B2 (en) 1997-04-28 2002-10-31 Aventis Pharma S.A. Adenovirus-mediated intratumoral delivery of an angiogenesis antagonist for the treatment of tumors
ES2210761T3 (en) * 1997-05-21 2004-07-01 The Board Of Trustees Of The Leland Stanford Junior University COMPOSITION AND PROCEDURE TO IMPROVE TRANSPORTATION THROUGH BIOLOGICAL MEMBERS.
US6958148B1 (en) 1998-01-20 2005-10-25 Pericor Science, Inc. Linkage of agents to body tissue using microparticles and transglutaminase
US6919076B1 (en) 1998-01-20 2005-07-19 Pericor Science, Inc. Conjugates of agents and transglutaminase substrate linking molecules
EP1054694A2 (en) 1998-02-13 2000-11-29 Selective Genetics, Inc. Concurrent flow mixing methods and apparatuses for the preparation of gene therapy vectors and compositions prepared thereby
US7101575B2 (en) 1998-03-19 2006-09-05 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Production of nanocapsules and microcapsules by layer-wise polyelectrolyte self-assembly
WO1999053961A1 (en) * 1998-04-23 1999-10-28 The Regents Of The University Of Michigan Peptides for efficient gene transfer
US6169078B1 (en) * 1998-05-12 2001-01-02 University Of Florida Materials and methods for the intracellular delivery of substances
US6171855B1 (en) 1998-05-28 2001-01-09 The Regents Of The University Of Michigan Vectors
US6927278B1 (en) * 1998-09-01 2005-08-09 Trustees Of The University Of Pennsylvania Peptide scaffolds for transfer of molecules into eukaryotic cells
US6696089B2 (en) 1998-09-03 2004-02-24 Board Of Regents Of The University Of Nebraska Nanogel networks including polyion polymer fragments and biological agent compositions thereof
US6077709A (en) 1998-09-29 2000-06-20 Isis Pharmaceuticals Inc. Antisense modulation of Survivin expression
CA2350882C (en) 1998-11-12 2011-02-22 Life Technologies Corporation Transfection reagents
US6773911B1 (en) 1998-11-23 2004-08-10 Amgen Canada Inc. Apoptosis-inducing factor
US6395029B1 (en) * 1999-01-19 2002-05-28 The Children's Hospital Of Philadelphia Sustained delivery of polyionic bioactive agents
US7098192B2 (en) 1999-04-08 2006-08-29 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of STAT3 expression
US6281005B1 (en) 1999-05-14 2001-08-28 Copernicus Therapeutics, Inc. Automated nucleic acid compaction device
US7674951B1 (en) 1999-05-21 2010-03-09 Michigan Technological University Isolated cellulose synthase promoter regions
US7049481B1 (en) 1999-05-21 2006-05-23 Board Of Control Of Michigan Technological University Cellulose synthase encoding polynucleotides and uses thereof
DE19929104A1 (en) * 1999-06-24 2000-12-28 Aventis Pharma Gmbh Vector complex, useful for gene therapy of e.g. tumors, comprises nucleic acid, cationic carrier, charged polymer and targeting ligand
US6770740B1 (en) 1999-07-13 2004-08-03 The Regents Of The University Of Michigan Crosslinked DNA condensate compositions and gene delivery methods
DE19933506A1 (en) * 1999-07-16 2001-01-25 Deutsches Krebsforsch Cellular uptake of DNA
DE19935302A1 (en) * 1999-07-28 2001-02-08 Aventis Pharma Gmbh Conjugates and processes for their preparation and their use for the transport of molecules across biological membranes
WO2001013723A1 (en) * 1999-08-20 2001-03-01 Mirus Corporation Charge reversal of polyion complexes
US7229961B2 (en) * 1999-08-24 2007-06-12 Cellgate, Inc. Compositions and methods for enhancing drug delivery across and into ocular tissues
US6730293B1 (en) 1999-08-24 2004-05-04 Cellgate, Inc. Compositions and methods for treating inflammatory diseases of the skin
US6669951B2 (en) * 1999-08-24 2003-12-30 Cellgate, Inc. Compositions and methods for enhancing drug delivery across and into epithelial tissues
WO2001013957A2 (en) 1999-08-24 2001-03-01 Cellgate, Inc. Enhancing drug delivery across and into epithelial tissues using oligo arginine moieties
US20010009759A1 (en) * 1999-12-08 2001-07-26 Jsr Corporation Virus-binding particles, virus-separating reagent, separation of viruses, and detection of viruses
CA2394758A1 (en) * 1999-12-29 2001-07-05 A. James Mixson Histidine-containing copolymers enhance pharmaceutical agent delivery
US7070807B2 (en) * 1999-12-29 2006-07-04 Mixson A James Branched histidine copolymers and methods for using same
US20020055479A1 (en) 2000-01-18 2002-05-09 Cowsert Lex M. Antisense modulation of PTP1B expression
US6261840B1 (en) 2000-01-18 2001-07-17 Isis Pharmaceuticals, Inc. Antisense modulation of PTP1B expression
US20030134420A1 (en) * 2000-02-18 2003-07-17 Lollo Charles Peter Methods and compositions for gene delivery
ATE511856T1 (en) 2000-03-13 2011-06-15 Cornell Res Foundation Inc BLOCKING LEUKOCYTE EMIGRATION AND INFLAMMATION DUE TO DISRUPTION WITH CD99/HEC2
GB0018307D0 (en) 2000-07-26 2000-09-13 Aventis Pharm Prod Inc Polypeptides
AU5345901A (en) 2000-04-13 2001-10-30 Univ Rockefeller Enhancement of antibody-mediated immune responses
AU2001257613A1 (en) * 2000-04-23 2001-11-12 Arizeke Pharmaceuticals, Inc. Compositions comprising carriers and transportable complexes
EP2287190B1 (en) 2000-05-10 2014-12-17 Mayo Foundation For Medical Education And Research Human igm antibodies with the capability of inducing remyelination, and diagnostic and therapeutic uses thereof particularly in the central nervous system
US6680172B1 (en) 2000-05-16 2004-01-20 Regents Of The University Of Michigan Treatments and markers for cancers of the central nervous system
US7355019B2 (en) * 2000-06-06 2008-04-08 Sibtech, Inc. Cysteine-containing peptide tag for site-specific conjugation of proteins
AU2001281168A1 (en) 2000-08-08 2002-02-18 St. Jude Children's Research Hospital Group b streptococcus polypeptides nucleic acids and therapeutic compositions and vaccines thereof
RU2190018C2 (en) * 2000-08-14 2002-09-27 Государственный научный центр вирусологии и биотехнологии "Вектор" Molecular vector for delivering genes to target cells
CA2422524A1 (en) * 2000-09-25 2002-03-28 Motoyuki Yamashita Pei: dna vector formulations for in vitro and in vivo gene delivery
US20030166160A1 (en) * 2001-09-06 2003-09-04 Hawley Stephen B. Compounds and molecular complexes comprising multiple binding regions directed to transcytotic ligands
IL155204A0 (en) * 2000-10-02 2003-11-23 Arizeke Pharmaceuticals Inc Compositions and methods for the transport of biologically active agents across cellular barriers
US8105825B2 (en) 2000-10-03 2012-01-31 Intrexon Corporation Multiple inducible gene regulation system
DE10049010A1 (en) * 2000-10-04 2002-04-18 Boehringer Ingelheim Int Transferrin polycation / DNA complexes for the systemic therapy of tumor diseases with cytotoxic proteins
BR0116756A (en) 2000-12-28 2005-01-04 Wyeth Corp Recombinant protective protein for streptococcus pneumoniae and its use
AU2002306550B2 (en) 2001-02-20 2007-10-25 Intrexon Corporation Novel substitution mutant receptors and their use in a nuclear receptor-based inducible gene expression system
CA2438119C (en) 2001-02-20 2014-12-16 Rheogene Holdings, Inc. Chimeric retinoid x receptors and their use in a novel ecdysone receptor-based inducible gene expression system
EP1499349B1 (en) 2001-03-02 2009-11-18 The Rockefeller University Recombinant hybrid allergen constructs with reduced allergenicity that retain immunogenicity of the natural allergen
WO2002076448A1 (en) * 2001-03-23 2002-10-03 Napro Biotherapeutics, Inc. Molecular conjugates for use in treatment of cancer
US20030096748A1 (en) * 2001-06-04 2003-05-22 The Regents Of The University Of Michigan Methods and compositions for the treatment of diseases associated with signal transduction aberrations
EP1409549A4 (en) 2001-06-20 2007-10-24 Genentech Inc COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING TUMORS
US7803915B2 (en) 2001-06-20 2010-09-28 Genentech, Inc. Antibody compositions for the diagnosis and treatment of tumor
CA2451643C (en) 2001-06-21 2012-11-13 Isis Pharmaceuticals, Inc. Antisense modulation of superoxide dismutase 1, soluble expression
US7425545B2 (en) 2001-07-25 2008-09-16 Isis Pharmaceuticals, Inc. Modulation of C-reactive protein expression
US6964950B2 (en) 2001-07-25 2005-11-15 Isis Pharmaceuticals, Inc. Antisense modulation of C-reactive protein expression
US20030096772A1 (en) 2001-07-30 2003-05-22 Crooke Rosanne M. Antisense modulation of acyl CoA cholesterol acyltransferase-2 expression
US7407943B2 (en) 2001-08-01 2008-08-05 Isis Pharmaceuticals, Inc. Antisense modulation of apolipoprotein B expression
US7227014B2 (en) 2001-08-07 2007-06-05 Isis Pharmaceuticals, Inc. Antisense modulation of apolipoprotein (a) expression
NZ573739A (en) 2001-09-18 2010-07-30 Genentech Inc Compositions and methods for the diagnosis and treatment of tumor, particularly colorectal tumor - TAT201
NZ577565A (en) 2001-10-09 2010-10-29 Isis Pharmaceuticals Inc Antisense modulation of insulin-like growth factor binding protein 5 expressions
US6750019B2 (en) 2001-10-09 2004-06-15 Isis Pharmaceuticals, Inc. Antisense modulation of insulin-like growth factor binding protein 5 expression
MX339524B (en) 2001-10-11 2016-05-30 Wyeth Corp NEW IMMUNOGENIC COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF MENINGOCOCICAL DISEASE.
US20030228319A1 (en) 2002-04-16 2003-12-11 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
JP2005527639A (en) 2001-11-02 2005-09-15 インサート セラピューティクス インコーポレイテッド Methods and compositions for therapeutic use of RNA interference
US6965025B2 (en) 2001-12-10 2005-11-15 Isis Pharmaceuticals, Inc. Antisense modulation of connective tissue growth factor expression
EP1575571A4 (en) 2002-01-02 2008-06-25 Genentech Inc COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING A TUMOR
EP1481268A4 (en) 2002-02-07 2005-06-29 Covalent Partners Llc Nanofilm and membrane compositions
US20030186916A1 (en) * 2002-03-12 2003-10-02 Lei Yu Vector for transfection of eukaryotic cells
US20030180712A1 (en) 2002-03-20 2003-09-25 Biostratum Ab Inhibition of the beta3 subunit of L-type Ca2+ channels
WO2003086272A2 (en) * 2002-04-16 2003-10-23 Kamada Ltd. Ultrapure transferrin for pharmaceutical compositions
US7199107B2 (en) 2002-05-23 2007-04-03 Isis Pharmaceuticals, Inc. Antisense modulation of kinesin-like 1 expression
US7074893B2 (en) * 2002-06-03 2006-07-11 Regents Of The University Of Michigan Methods and compositions for the treatment of diseases associated with signal transduction aberrations
GB0215534D0 (en) * 2002-07-04 2002-08-14 Ecole Polytech Selective photochemotherapy using oligonucleotide targeting agents
US7375093B2 (en) 2002-07-05 2008-05-20 Intrexon Corporation Ketone ligands for modulating the expression of exogenous genes via an ecdysone receptor complex
US7785608B2 (en) 2002-08-30 2010-08-31 Wyeth Holdings Corporation Immunogenic compositions for the prevention and treatment of meningococcal disease
EA008940B1 (en) 2002-09-13 2007-10-26 Репликор, Инк. Non-sequence complementary antiviral oligonucleotides
AU2003278957A1 (en) 2002-09-26 2004-04-23 Amgen, Inc. Modulation of forkhead box o1a expression
US8604183B2 (en) 2002-11-05 2013-12-10 Isis Pharmaceuticals, Inc. Compositions comprising alternating 2′-modified nucleosides for use in gene modulation
WO2004044138A2 (en) 2002-11-05 2004-05-27 Isis Pharmaceuticals, Inc. Chimeric oligomeric compounds and their use in gene modulation
SI1569695T1 (en) 2002-11-13 2013-08-30 Genzyme Corporation Antisense modulation of apolipoprotein b expression
AU2003294281B2 (en) 2002-11-13 2010-05-20 Kastle Therapeutics, Llc Antisense modulation of apolipoprotein B expression
US7144999B2 (en) 2002-11-23 2006-12-05 Isis Pharmaceuticals, Inc. Modulation of hypoxia-inducible factor 1 alpha expression
US7465708B2 (en) 2002-11-25 2008-12-16 Mixson A James Branched cationic copolymers and methods for antimicrobial use
US7304161B2 (en) 2003-02-10 2007-12-04 Intrexon Corporation Diaclhydrazine ligands for modulating the expression of exogenous genes in mammalian systems via an ecdysone receptor complex
EP1597366B1 (en) 2003-02-11 2012-11-21 Antisense Therapeutics Ltd Modulation of insulin like growth factor i receptor expression
US7456315B2 (en) 2003-02-28 2008-11-25 Intrexon Corporation Bioavailable diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex
US7803781B2 (en) 2003-02-28 2010-09-28 Isis Pharmaceuticals, Inc. Modulation of growth hormone receptor expression and insulin-like growth factor expression
US20040185559A1 (en) 2003-03-21 2004-09-23 Isis Pharmaceuticals Inc. Modulation of diacylglycerol acyltransferase 1 expression
US7598227B2 (en) 2003-04-16 2009-10-06 Isis Pharmaceuticals Inc. Modulation of apolipoprotein C-III expression
AU2004231740A1 (en) * 2003-04-17 2004-11-04 The Trustees Of Columbia University In The City Ofnew York Desmoglein 4 is a novel gene involved in hair growth
US7399853B2 (en) 2003-04-28 2008-07-15 Isis Pharmaceuticals Modulation of glucagon receptor expression
JP4579911B2 (en) 2003-06-03 2010-11-10 アイシス・ファーマシューティカルズ・インコーポレイテッド Regulation of survivin expression
DE602004028837D1 (en) 2003-07-03 2010-10-07 Univ New Jersey Med GENES AS DIAGNOSTIC TOOLS FOR AUTISM
WO2005013901A2 (en) 2003-07-31 2005-02-17 Isis Pharmaceuticals, Inc. Oligomeric compounds and compositions for use in modulation of small non-coding rnas
US7825235B2 (en) 2003-08-18 2010-11-02 Isis Pharmaceuticals, Inc. Modulation of diacylglycerol acyltransferase 2 expression
EP2182063A3 (en) 2003-09-18 2012-07-18 Isis Pharmaceuticals, Inc. Modulation of EIF4E expression
WO2005035548A1 (en) 2003-10-10 2005-04-21 Meditech Research Limited The moduilation of hyaluronan synthesis and degradation in the treatment of disease
AU2004297533B2 (en) 2003-10-24 2010-04-29 Gencia Corporation Methods and compositions for delivering polynucleotides
US8133733B2 (en) 2003-10-24 2012-03-13 Gencia Corporation Nonviral vectors for delivering polynucleotides to target tissues
US8507277B2 (en) 2003-10-24 2013-08-13 Gencia Corporation Nonviral vectors for delivering polynucleotides
US8062891B2 (en) 2003-10-24 2011-11-22 Gencia Corporation Nonviral vectors for delivering polynucleotides to plants
US20090123468A1 (en) 2003-10-24 2009-05-14 Gencia Corporation Transducible polypeptides for modifying metabolism
US20050191653A1 (en) 2003-11-03 2005-09-01 Freier Susan M. Modulation of SGLT2 expression
NZ576411A (en) 2003-11-17 2010-04-30 Genentech Inc Compositions and methods for the treatment of tumor of hematopoietic origin
WO2005071080A2 (en) 2004-01-20 2005-08-04 Isis Pharmaceuticals, Inc. Modulation of glucocorticoid receptor expression
US7468431B2 (en) 2004-01-22 2008-12-23 Isis Pharmaceuticals, Inc. Modulation of eIF4E-BP2 expression
US8569474B2 (en) 2004-03-09 2013-10-29 Isis Pharmaceuticals, Inc. Double stranded constructs comprising one or more short strands hybridized to a longer strand
WO2005089268A2 (en) 2004-03-15 2005-09-29 Isis Pharmaceuticals, Inc. Compositions and methods for optimizing cleavage of rna by rnase h
DE102004013637A1 (en) 2004-03-19 2005-10-13 Capsulution Nanoscience Ag Process for the preparation of CS particles and microcapsules using porous templates as well as CS particles and microcapsules
WO2005097207A2 (en) * 2004-03-26 2005-10-20 Curis, Inc. Rna interference modulators of hedgehog signaling and uses thereof
US20050244869A1 (en) 2004-04-05 2005-11-03 Brown-Driver Vickie L Modulation of transthyretin expression
DK1745295T3 (en) 2004-04-20 2011-01-31 Galapagos Nv Methods, compositions and compound assays to inhibit the production of amyloid beta protein
CA2562833A1 (en) 2004-04-27 2005-11-03 Galapagos N.V. Methods, agents, and compound screening assays for inducing differentiation of undifferentiated mammalian cells into osteoblasts
US7935510B2 (en) 2004-04-30 2011-05-03 Intrexon Corporation Mutant receptors and their use in a nuclear receptor-based inducible gene expression system
US20090048192A1 (en) * 2004-06-03 2009-02-19 Isis Pharmaceuticals, Inc. Double Strand Compositions Comprising Differentially Modified Strands for Use in Gene Modulation
US8394947B2 (en) 2004-06-03 2013-03-12 Isis Pharmaceuticals, Inc. Positionally modified siRNA constructs
US7306923B2 (en) 2004-06-14 2007-12-11 Galapagos N.V. Methods for identification, and compounds useful for the treatment of degenerative & inflammatory diseases
TW200613554A (en) 2004-06-17 2006-05-01 Wyeth Corp Plasmid having three complete transcriptional units and immunogenic compositions for inducing an immune response to HIV
US20070004658A1 (en) 2004-06-21 2007-01-04 Nick Vandeghinste Method and means for treatment of osteoarthritis
US7884086B2 (en) 2004-09-08 2011-02-08 Isis Pharmaceuticals, Inc. Conjugates for use in hepatocyte free uptake assays
EP1799825B1 (en) 2004-10-05 2011-06-29 The California Institute of Technology Aptamer regulated nucleic acids and uses thereof
US8673268B2 (en) 2004-10-15 2014-03-18 Galapagos N.V. Molecular targets and compounds, and methods to identify the same, useful in the treatment of joint degenerative and inflammatory diseases
US7485468B2 (en) 2004-10-15 2009-02-03 Galapagos Bv Molecular targets and compounds, and methods to identify the same, useful in the treatment of joint degenerative and inflammatory diseases
US9034650B2 (en) 2005-02-02 2015-05-19 Intrexon Corporation Site-specific serine recombinases and methods of their use
WO2006086667A2 (en) 2005-02-09 2006-08-17 Avi Bio Pharma, Inc. Antisense composition and method for treating muscle atrophy
MX2007010922A (en) 2005-03-10 2007-10-12 Genentech Inc Methods and compositions for modulating vascular integrity.
PL1866414T3 (en) 2005-03-31 2012-10-31 Calando Pharmaceuticals Inc Inhibitors of ribonucleotide reductase subunit 2 and uses thereof
US8088382B2 (en) 2005-07-05 2012-01-03 Cornell Research Foundation, Inc. Methods of inhibiting transendothelial migration of neutrophils and monocytes with anti-CD99L2 antibodies
US8129585B2 (en) 2005-08-03 2012-03-06 Michigan Technological University Methods for enhancing expression of secondary cell wall cellulose synthases in plants
CA2630602A1 (en) 2005-11-21 2007-05-31 Isis Pharmaceuticals, Inc. Modulation of eif4e-bp2 expression
EP2422819B1 (en) 2006-01-26 2017-03-01 Ionis Pharmaceuticals, Inc. Compositions and their uses directed to Huntingtin
CA2647277A1 (en) 2006-04-05 2007-11-08 Genentech, Inc. Method for using boc/cdo to modulate hedgehog signaling
CN101437943A (en) 2006-05-03 2009-05-20 波罗的科技发展有限公司 Antisense agents combining strongly bound base - modified oligonucleotide and artificial nuclease
WO2008011473A2 (en) 2006-07-19 2008-01-24 Isis Pharmaceuticals, Inc. Compositions and their uses directed to hbxip
MY151438A (en) 2006-07-28 2014-05-30 Sanofi Aventis Compositions and method for treatment of tumors
US8158595B2 (en) 2006-11-09 2012-04-17 California Institute Of Technology Modular aptamer-regulated ribozymes
WO2008073856A2 (en) * 2006-12-08 2008-06-19 Massachusetts Institute Of Technology Delivery of nanoparticles and/or agents to cells
AR064642A1 (en) 2006-12-22 2009-04-15 Wyeth Corp POLINUCLEOTIDE VECTOR THAT INCLUDES IT RECOMBINATING CELL THAT UNDERSTANDS THE VECTOR POLYPEPTIDE, ANTIBODY, COMPOSITION THAT UNDERSTANDS THE POLINUCLEOTIDE, VECTOR, RECOMBINATING CELL POLYPEPTIDE OR ANTIBODY, USE OF THE COMPOSITION AND A COMPOSITION AND A METHOD
WO2008086807A2 (en) * 2007-01-19 2008-07-24 Exiqon A/S Mediated cellular delivery of lna oligonucleotides
WO2008094945A2 (en) 2007-01-29 2008-08-07 Isis Pharmaceuticals, Inc. Compounds and methods for modulating protein expression
RU2502806C2 (en) 2007-02-22 2013-12-27 Дженентек, Инк. Detection method of intestine inflammatory disease
CN101679498B (en) * 2007-04-05 2013-07-31 西姆拜奥泰克生物技术领域研究开发有限责任公司 Dimethionine histone
MX363066B (en) 2007-05-29 2019-03-07 Intrexon Corp Chiral diachylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex.
HRP20140405T1 (en) 2007-06-20 2014-06-20 Galapagos N.V. Molecular targets and compounds, and methods to identify the same, useful in the treatment of bone and joint degenerative diseases
US20090082217A1 (en) * 2007-07-16 2009-03-26 California Institute Of Technology Selection of nucleic acid-based sensor domains within nucleic acid switch platform
US20090098055A1 (en) 2007-08-23 2009-04-16 Intrexon Corporation Methods and Compositions for Diagnosing Disease
US20120165387A1 (en) 2007-08-28 2012-06-28 Smolke Christina D General composition framework for ligand-controlled RNA regulatory systems
US8367815B2 (en) * 2007-08-28 2013-02-05 California Institute Of Technology Modular polynucleotides for ligand-controlled regulatory systems
US8865667B2 (en) * 2007-09-12 2014-10-21 California Institute Of Technology Higher-order cellular information processing devices
MX2010002777A (en) * 2007-09-17 2010-05-21 Rohm & Haas Compositions and methods for the modification of physiological responses in plants.
DK2205618T3 (en) 2007-09-26 2017-02-20 Intrexon Corp SYNTHETIC 5 'NON-TRANSLATED REGIONS, EXPRESSION VECTORS AND PROCEDURES FOR INCREASING TRANSGENIC EXPRESSION
US20090136465A1 (en) 2007-09-28 2009-05-28 Intrexon Corporation Therapeutic Gene-Switch Constructs and Bioreactors for the Expression of Biotherapeutic Molecules, and Uses Thereof
CA2700953A1 (en) 2007-10-02 2009-04-09 Amgen Inc. Increasing erythropoietin using nucleic acids hybridizable to micro-rna and precursors thereof
US7973019B1 (en) * 2007-10-03 2011-07-05 Alcon Research, Ltd. Transferrin/transferrin receptor-mediated siRNA delivery
JP2010539993A (en) 2007-10-08 2010-12-24 イントレキソン コーポレーション Use for the treatment of genetically engineered dendritic cells and cancer
WO2009065618A2 (en) 2007-11-22 2009-05-28 Biontex Laboratories Gmbh Improvement of transfection results of non-viral gene delivery systems by influencing the congenital immune system
DE102007056488A1 (en) 2007-11-22 2009-07-23 Biontex Laboratories Gmbh Composition, useful e.g. transfection comprises a non-viral gene delivery system containing e.g. cationic lipid, and an agent for partial suppression and/or activation of innate intracellular and/or intercellular immune defense
DE102008016275A1 (en) 2008-03-28 2009-11-19 Biontex Laboratories Gmbh Composition, useful e.g. transfection comprises a non-viral gene delivery system containing e.g. cationic lipid, and an agent for partial suppression and/or activation of innate intracellular and/or intercellular immune defense
DE102008023913A1 (en) 2008-05-16 2009-11-19 Biontex Laboratories Gmbh Composition, useful e.g. transfection comprises a non-viral gene delivery system containing e.g. cationic lipid, and an agent for partial suppression and/or activation of innate intracellular and/or intercellular immune defense
US9029524B2 (en) * 2007-12-10 2015-05-12 California Institute Of Technology Signal activated RNA interference
JP2011516065A (en) 2008-04-04 2011-05-26 カランド ファーマシューティカルズ， インコーポレイテッド Compositions and uses of EPAS1 inhibitors
US8093043B2 (en) 2008-06-04 2012-01-10 New York University β-TrCP1, β-TrCP2 and RSK1 or RSK2 inhibitors and methods for sensitizing target cells to apoptosis
US8815818B2 (en) 2008-07-18 2014-08-26 Rxi Pharmaceuticals Corporation Phagocytic cell delivery of RNAI
CN107083386A (en) 2008-08-25 2017-08-22 埃克斯雷德制药有限公司 Prevent GEM 132 of CTGF and application thereof
AU2009290848A1 (en) 2008-09-11 2010-03-18 Galapagos Nv Method for identifying compounds useful for increasing the functional activity and cell surface expression of CF-associated mutant Cystic Fibrosis transmembrane conductance regulator
EP2342340A1 (en) 2008-09-22 2011-07-13 Rxi Pharmaceuticals Corporation Rna interference in skin indications
AU2009313615B2 (en) 2008-11-05 2012-11-29 Regents Of The University Of Minnesota Multicomponent immunogenic composition for the prevention of beta-hemolytic streptococcal (BHS) disease
KR20110091796A (en) 2008-12-04 2011-08-12 오피케이오 큐알엔에이, 엘엘씨 Treatment of Tumor Suppressor-Related Diseases by Inhibition of Natural Antisense Transcripts Against Tumor Suppressor Genes
CA2745329C (en) 2008-12-04 2022-07-12 Opko Curna, Llc Treatment of erythropoietin (epo) related diseases by inhibition of natural antisense transcript to epo
JP6099868B2 (en) 2008-12-04 2017-03-22 クルナ・インコーポレーテッド Treatment of sirtuin 1 related diseases by suppression of natural antisense transcripts against sirtuin 1 (SIRT1)
US9493774B2 (en) 2009-01-05 2016-11-15 Rxi Pharmaceuticals Corporation Inhibition of PCSK9 through RNAi
WO2010090762A1 (en) 2009-02-04 2010-08-12 Rxi Pharmaceuticals Corporation Rna duplexes with single stranded phosphorothioate nucleotide regions for additional functionality
EP2216341A1 (en) 2009-02-10 2010-08-11 Novozymes Biopharma UK Limited Transferrin variants and conjugates
JP6066035B2 (en) 2009-02-12 2017-01-25 クルナ・インコーポレーテッド Treatment of glial cell-derived neurotrophic factor (GDNF) -related diseases by suppression of natural antisense transcripts against GDNF
HUE026280T2 (en) 2009-02-12 2016-06-28 Curna Inc Treatment of brain derived neurotrophic factor (bdnf) related diseases by inhibition of natural antisense transcript to bdnf
US8329882B2 (en) 2009-02-18 2012-12-11 California Institute Of Technology Genetic control of mammalian cells with synthetic RNA regulatory systems
EP2398481A2 (en) 2009-02-19 2011-12-28 Galapagos N.V. Methods for identifying and compounds useful for the diagnosis and treatment of diseases involving inflammation
EP2398480A1 (en) 2009-02-19 2011-12-28 Galapagos N.V. Methods for identifying and compounds useful for the diagnosis and treatment of diseases involving inflammation
US20120004160A1 (en) 2009-02-19 2012-01-05 Glaxo Group Ltd. Methods for identifying and compounds useful for the diagnosis and treatment of diseases involving inflammation
EP2963116B1 (en) 2009-03-04 2020-11-11 CuRNA, Inc. Treatment of sirtuin 1 (sirt1) related diseases by inhibition of natural antisense transcript to sirt 1
MX2011009751A (en) 2009-03-16 2011-09-29 Opko Curna Llc Treatment of nuclear factor (erythroid-derived 2)-like 2 (nrf2) related diseases by inhibition of natural antisense transcript to nrf2.
US9708604B2 (en) 2009-03-17 2017-07-18 Curna, Inc. Treatment of delta-like 1 homolog (DLK1) related diseases by inhibition of natural antisense transcript to DLK1
WO2010112569A1 (en) 2009-03-31 2010-10-07 Robert Zimmermann Modulation of adipose triglyceride lipase for prevention and treatment of cachexia, loss of weight and muscle atrophy and methods of screening therefor
US8993509B2 (en) 2009-03-31 2015-03-31 Robert Zimmerman Method for treatment of cachexia by administering inhibitors of adipose triglyceride lipase expression or activity
EP3043179B1 (en) 2009-04-01 2020-05-06 Galapagos N.V. Methods and means for treatment of osteoarthritis
US9145555B2 (en) 2009-04-02 2015-09-29 California Institute Of Technology Integrated—ligand-responsive microRNAs
JP5822822B2 (en) 2009-04-17 2015-11-24 ニューヨーク ユニバーシティ Peptides that target TNF family receptors and antagonize TNF action, compositions, methods and uses thereof
EP3524275A1 (en) 2009-04-22 2019-08-14 Massachusetts Institute Of Technology Innate immune supression enables repeated delivery of long rna molecules
WO2010127195A2 (en) 2009-05-01 2010-11-04 Curna, Inc. Antisense oligonucleotides of hemoglobins
CN102459596B (en) 2009-05-06 2016-09-07 库尔纳公司 Treatment of Lipid Transport and Metabolism Gene-Associated Diseases by Inhibition of Natural Antisense Transcripts Targeting Lipid Transport and Metabolism Genes
ES2609655T3 (en) 2009-05-06 2017-04-21 Curna, Inc. Treatment of diseases related to tristetraproline (TTP) by inhibition of natural antisense transcript for TTP
DK2432881T3 (en) 2009-05-18 2018-02-26 Curna Inc TREATMENT OF REPROGRAMMING FACTOR-RELATED DISEASES BY INHIBITING NATURAL ANTISENSE TRANSCRIPTS TO A REPROGRAMMING FACTOR
KR101703695B1 (en) 2009-05-22 2017-02-08 큐알엔에이, 인크. Treatment of transcription factor e3 (tfe3) and insulin receptor substrate 2 (irs2) related diseases by inhibition of natural antisense transcript to tfe3
KR101704988B1 (en) 2009-05-28 2017-02-08 큐알엔에이, 인크. Treatment of antiviral gene related diseases by inhibition of natural antisense transcript to an antiviral gene
ES2629339T3 (en) 2009-06-16 2017-08-08 Curna, Inc. Treatment of diseases related to paraoxonase 1 (pon1) by inhibition of natural antisense transcript to pon1
WO2010148050A2 (en) 2009-06-16 2010-12-23 Curna, Inc. Treatment of collagen gene related diseases by inhibition of natural antisense transcript to a collagen gene
ES2618894T3 (en) 2009-06-24 2017-06-22 Curna, Inc. TREATMENT OF DISEASES RELATED TO THE RECEIVER OF THE TUMOR NECROSIS FACTOR 2 (TNFR2) BY INHIBITION OF THE ANTISENTED NATURAL TRANSCRIPT FOR TNFR2
CN102482672B (en) 2009-06-26 2016-11-09 库尔纳公司 By suppressing the natural antisense transcript treatment Down syndrome gene-associated diseases of Down syndrome gene
WO2011015572A1 (en) 2009-08-03 2011-02-10 Galapagos Nv Molecular targets and compounds, and methods to identify the same, useful in the treatment of neurodegenerative diseases
WO2011015573A1 (en) 2009-08-03 2011-02-10 Galapagos Nv Molecular targets and compounds, and methods to identify the same, useful in the treatment of neurodegenerative diseases
CA2769665A1 (en) 2009-08-05 2011-02-10 Opko Curna, Llc Treatment of insulin gene (ins) related diseases by inhibition of natural antisense transcript to an insulin gene (ins)
CN102482671B (en) 2009-08-25 2017-12-01 库尔纳公司 Treatment of IQGAP-associated diseases by inhibiting the natural antisense transcript of 'IQ motif-containing GTPase-activating protein' (IQGAP)
JP5887270B2 (en) 2009-09-02 2016-03-16 ジェネンテック， インコーポレイテッド Mutant SMOOTHENED AND METHOD OF USING THE SAME
AU2010306940A1 (en) 2009-10-12 2012-06-07 Smith, Larry Methods and compositions for modulating gene expression using oligonucleotide based drugs administered in vivo or in vitro
RU2539772C2 (en) 2009-10-22 2015-01-27 Дженентек, Инк. Methods and compositions for hepsin modulation of macrophage-stimulating protein
WO2011056234A1 (en) 2009-11-06 2011-05-12 Fibrogen, Inc. Treatment for radiation-induced disorders
TWI507524B (en) 2009-11-30 2015-11-11 建南德克公司 Composition and method for diagnosing and treating tumor
WO2011070177A2 (en) 2009-12-11 2011-06-16 Baltic Technology Development, Ltd. Methods of facilitating neural cell survival using gdnf family ligand (gfl) mimetics or ret signaling pathway activators
CA2782366A1 (en) 2009-12-16 2011-07-14 Opko Curna, Llc Treatment of membrane bound transcription factor peptidase, site 1 (mbtps1) related diseases by inhibition of natural antisense transcript to mbtps1
EP2515947B1 (en) 2009-12-23 2021-10-06 CuRNA, Inc. Treatment of uncoupling protein 2 (ucp2) related diseases by inhibition of natural antisense transcript to ucp2
US8940708B2 (en) 2009-12-23 2015-01-27 Curna, Inc. Treatment of hepatocyte growth factor (HGF) related diseases by inhibition of natural antisense transcript to HGF
US8921334B2 (en) 2009-12-29 2014-12-30 Curna, Inc. Treatment of nuclear respiratory factor 1 (NRF1) related diseases by inhibition of natural antisense transcript to NRF1
ES2585829T3 (en) 2009-12-29 2016-10-10 Curna, Inc. Treatment of diseases related to tumor protein 63 (p63) by inhibition of natural antisense transcription to p63
US8946181B2 (en) 2010-01-04 2015-02-03 Curna, Inc. Treatment of interferon regulatory factor 8 (IRF8) related diseases by inhibition of natural antisense transcript to IRF8
RU2612161C2 (en) 2010-01-06 2017-03-02 Курна, Инк. Treatment of pancreatic developmental gene related diseases by inhibition of natural antisense transcript to pancreatic developmental gene
NO2524039T3 (en) 2010-01-11 2018-04-28
EP2525808A2 (en) 2010-01-19 2012-11-28 The Trustees Of Columbia University In The City Of New York Osteocalcin as a treatment for male reproductive disorders
ES2671877T3 (en) 2010-01-25 2018-06-11 Curna, Inc. Treatment of diseases related to RNASA (H1) by inhibition of the natural antisense transcript to RNASA H1
WO2011103528A2 (en) 2010-02-22 2011-08-25 Opko Curna Llc Treatment of pyrroline-5-carboxylate reductase 1 (pycr1) related diseases by inhibition of natural antisense transcript to pycr1
AU2011221226A1 (en) 2010-02-23 2012-08-16 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
EP2550359B1 (en) 2010-03-23 2017-08-09 Intrexon Corporation Vectors conditionally expressing therapeutic proteins, host cells comprising the vectors, and uses thereof
WO2011119852A1 (en) 2010-03-24 2011-09-29 Rxi Pharmaceuticals Corporation Reduced size self-delivering rnai compounds
WO2011127337A2 (en) 2010-04-09 2011-10-13 Opko Curna Llc Treatment of fibroblast growth factor 21 (fgf21) related diseases by inhibition of natural antisense transcript to fgf21
ES2625689T3 (en) 2010-04-29 2017-07-20 Ionis Pharmaceuticals, Inc. Modulation of transthyretin expression
RU2693462C2 (en) 2010-05-03 2019-07-03 Курна, Инк. Treatment of sirtuin (sirt) related diseases by inhibition of natural antisense transcript to sirtuin (sirt)
CN102958941A (en) 2010-05-03 2013-03-06 霍夫曼-拉罗奇有限公司 Compositions and methods for tumor diagnosis and treatment
ES2705236T3 (en) 2010-05-12 2019-03-22 Univ Columbia Procedures for producing enteroendocrine cells that produce and secrete insulin
TWI586356B (en) 2010-05-14 2017-06-11 可娜公司 Treatment of par4 related diseases by inhibition of natural antisense transcript to par4
WO2011150005A2 (en) 2010-05-26 2011-12-01 Opko Curna Llc Treatment of atonal homolog 1 (atoh1) related diseases by inhibition of natural antisense transcript to atoh1
CN103068982B (en) 2010-07-14 2017-06-09 库尔纳公司 DLG relevant diseases are treated by suppressing the natural antisense transcript of the big homologue of plate-like (DLG)
CA2808975C (en) 2010-08-23 2018-10-30 Wyeth Llc Stable formulations of neisseria meningitidis rlp2086 antigens
KR101584871B1 (en) 2010-09-10 2016-01-22 와이어쓰 엘엘씨 Non-lipidated variants of neisseria meningitidis orf2086 antigens
US8481680B2 (en) 2010-10-05 2013-07-09 Genentech, Inc. Mutant smoothened and methods of using the same
US8993533B2 (en) 2010-10-06 2015-03-31 Curna, Inc. Treatment of sialidase 4 (NEU4) related diseases by inhibition of natural antisense transcript to NEU4
CN103180445B (en) 2010-10-22 2018-02-16 库尔纳公司 IDUA relevant diseases are treated by suppressing the natural antisense transcript of α L iduronases (IDUA)
EP2633052B1 (en) 2010-10-27 2018-04-11 CuRNA, Inc. Treatment of interferon-related developmental regulator 1 (ifrd1) related diseases by inhibition of natural antisense transcript to ifrd1
WO2012061811A2 (en) 2010-11-05 2012-05-10 Fibrogen, Inc. Treatment method for lung remodeling diseases
US8987225B2 (en) 2010-11-23 2015-03-24 Curna, Inc. Treatment of NANOG related diseases by inhibition of natural antisense transcript to NANOG
DK2670411T3 (en) 2011-02-02 2019-05-13 Excaliard Pharmaceuticals Inc Antisense compounds directed at connective tissue growth factor (CTGF) for use in a method of treating keloids or hypertrophic scars
WO2012109495A1 (en) 2011-02-09 2012-08-16 Metabolic Solutions Development Company, Llc Cellular targets of thiazolidinediones
EP2681327B1 (en) 2011-03-04 2018-11-21 Intrexon Corporation Vectors conditionally expressing protein
CN105886506A (en) 2011-04-13 2016-08-24 Isis制药公司 Antisense modulation of PTP1B expression
WO2012170771A1 (en) 2011-06-09 2012-12-13 Curna, Inc. Treatment of frataxin (fxn) related diseases by inhibition of natural antisense transcript to fxn
AU2012271357A1 (en) 2011-06-16 2013-05-02 Ionis Pharmaceuticals, Inc. Antisense modulation of fibroblast growth factor receptor 4 expression
FR2979919B1 (en) 2011-09-12 2015-12-11 Centre Nat Rech Scient NON-INTEGRATIVE CHIMERIC LENTIVIRAL GENOMES AS INNOVATIVE VACCINES AGAINST HIV-1
BR112014006535A2 (en) 2011-09-20 2017-03-28 Univ North Carolina Chapel Hill regulation of sodium channels by plunc proteins
EP2758533B1 (en) 2011-09-20 2018-04-11 Ionis Pharmaceuticals, Inc. Antisense modulation of gcgr expression
FR2980801B1 (en) 2011-09-29 2016-02-05 Centre Nat Rech Scient USE OF RECOMBINANT "POLYKETIDE SYNTHASES" TYPE III (PKS III) OF MARINE BROWN ALGAE
US20130085139A1 (en) 2011-10-04 2013-04-04 Royal Holloway And Bedford New College Oligomers
AU2012328680A1 (en) 2011-10-25 2014-05-01 Ionis Pharmaceuticals, Inc. Antisense modulation of GCCR expression
SA115360586B1 (en) 2012-03-09 2017-04-12 فايزر انك Neisseria meningitidis compositions and methods thereof
CA2865745C (en) 2012-03-09 2018-01-09 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
ES2694592T3 (en) 2012-03-15 2018-12-21 Curna, Inc. Treatment of diseases related to brain-derived neurotrophic factor (BDNF) by inhibition of the natural antisense transcript of BDNF
WO2014041179A1 (en) 2012-09-17 2014-03-20 Chemedest Ltd. Treatment of peripheral neuropathy using gfr(alpha)3 type receptor agonists
WO2014066167A1 (en) 2012-10-22 2014-05-01 Fountain Biopharma Inc. Antibodies to interleukin-6 and uses thereof
CA2889044A1 (en) 2012-11-15 2014-05-22 Roche Innovation Center Copenhagen A/S Anti apob antisense conjugate compounds
CA2903716C (en) 2013-03-08 2019-04-09 Pfizer Inc. Immunogenic fusion polypeptides
US9952202B2 (en) 2013-03-14 2018-04-24 Galapagos Nv Methods of identifying compounds for the treatment of fibrosis by using S1PR5
JP6437467B2 (en) 2013-03-14 2018-12-19 ガラパゴス・ナムローゼ・フェンノートシャップＧａｌａｐａｇｏｓ Ｎ．Ｖ． Molecular targets and compounds useful in the treatment of fibrotic diseases and methods for identifying them
JP2016522675A (en) 2013-03-14 2016-08-04 ガラパゴス・ナムローゼ・フェンノートシャップＧａｌａｐａｇｏｓ Ｎ．Ｖ． Molecular targets useful in the treatment of diseases associated with epithelial-mesenchymal transition and inhibitors of said targets
US10052364B2 (en) 2013-03-15 2018-08-21 The Trustees Of Columbia University In The City Of New York Osteocalcin as a treatment for cognitive disorders
DK3007704T3 (en) 2013-06-13 2021-03-29 Antisense Therapeutics Ltd Combination therapy for acromegaly
AU2014317961B2 (en) 2013-09-05 2020-07-30 Murdoch University Antisense-induced exon2 inclusion in acid alpha-glucosidase
RU2662968C2 (en) 2013-09-08 2018-07-31 Пфайзер Инк. Immunogenic composition for neisseria meningitidis (options)
EP3047023B1 (en) 2013-09-19 2019-09-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Compositions and methods for inhibiting jc virus (jcv)
WO2015116902A1 (en) 2014-01-31 2015-08-06 Genentech, Inc. G-protein coupled receptors in hedgehog signaling
US20170044232A1 (en) 2014-02-04 2017-02-16 Genentech, Inc. Mutant smoothened and methods of using the same
KR101605421B1 (en) 2014-03-05 2016-03-23 국립암센터 A monoclonal antibody which specifically recognizes B cell lymphoma and use thereof
WO2015171918A2 (en) 2014-05-07 2015-11-12 Louisiana State University And Agricultural And Mechanical College Compositions and uses for treatment thereof
GB2526867A (en) 2014-06-05 2015-12-09 Oxitec Ltd Gene expression system
CA2985344A1 (en) 2014-06-26 2015-12-30 The Trustees Of Columbia University In The City Of New York Inhibition of serotonin expression in gut enteroendocrine cells results in conversion to insulin-positive cells
US10195280B2 (en) 2014-07-15 2019-02-05 Life Technologies Corporation Compositions and methods for efficient delivery of molecules to cells
WO2016033424A1 (en) 2014-08-29 2016-03-03 Genzyme Corporation Methods for the prevention and treatment of major adverse cardiovascular events using compounds that modulate apolipoprotein b
WO2016081728A1 (en) 2014-11-19 2016-05-26 The Trustees Of Columbia University In The City Of New York Osteocalcin as a treatment for frailty associated with aging
KR102554850B1 (en) 2015-02-06 2023-07-13 더 유니버시티 오브 노쓰 캐롤라이나 엣 채플 힐 Optimized human coagulation factor VIII gene expression cassette and use thereof
KR20190049940A (en) 2015-02-19 2019-05-09 화이자 인코포레이티드 Neisseria meningitidis compositions and methods thereof
MA41795A (en) 2015-03-18 2018-01-23 Sarepta Therapeutics Inc EXCLUSION OF AN EXON INDUCED BY ANTISENSE COMPOUNDS IN MYOSTATIN
US10849917B2 (en) 2015-06-01 2020-12-01 Sarepta Therapeutics, Inc. Antisense-induced exon exclusion in type VII collagen
US10954300B2 (en) 2015-09-28 2021-03-23 The Trustees Of Columbia University In The City Of New York Use of pentoxifylline with immune checkpoint-blockade therapies for the treatment of melanoma
JP2018530560A (en) 2015-10-09 2018-10-18 サレプタ セラピューティクス， インコーポレイテッド Compositions and methods for the treatment of Duchenne muscular dystrophy and related disorders
AU2016334401A1 (en) 2015-10-10 2018-04-26 Intrexon Corporation Improved therapeutic control of proteolytically sensitive, destabilized forms of interleukin-12
EP3370734B1 (en) 2015-11-05 2023-01-04 Children's Hospital Los Angeles Antisense oligo for use in treating acute myeloid leukemia
CN106699889A (en) 2015-11-18 2017-05-24 礼进生物医药科技（上海）有限公司 PD-1 resisting antibody and treatment application thereof
AU2016377398B2 (en) 2015-12-23 2022-10-13 Repluca Pty Ltd Nucleic acid oligomers and uses therefor
US10619159B2 (en) 2016-01-19 2020-04-14 The University Of North Carolina At Chapel Hill Methods and compositions using RNA interference for inhibition of KRAS
AU2017213826A1 (en) 2016-02-04 2018-08-23 Curis, Inc. Mutant smoothened and methods of using the same
JP2019512216A (en) 2016-02-22 2019-05-16 ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル Calcium channel peptide inhibitors
US11060089B2 (en) 2016-04-18 2021-07-13 Sarepta Therapeutics, Inc. Antisense oligomers and methods of using the same for treating diseases associated with the acid alpha-glucosidase gene
BR112019002771A2 (en) 2016-08-12 2019-05-14 Oxitec Ltd doublesex union control module polynucleotide, gene expression system, expression vector plasmid, genetically engineered insect, methods for producing genetically engineered insects, for selectively cultivating genetically engineered male insects, for reducing a wild insect population, for breeding a transgenic aedes aegypti mosquito and to detect the presence of a dna molecule, chromosomal target site of aedes aegypti, genetically engineered aedes aegypti mosquito, dna molecule, and dna detection kit.
AU2017359342B2 (en) 2016-11-09 2022-02-17 Intrexon Corporation Frataxin expression constructs
SG11201906519RA (en) 2017-01-31 2019-08-27 Pfizer Neisseria meningitidis compositions and methods thereof
US12440578B2 (en) 2017-02-22 2025-10-14 Io Biosciences, Inc. Nucleic acid constructs comprising gene editing multi-sites and uses thereof
JP7167059B2 (en) 2017-04-19 2022-11-08 フィオ ファーマシューティカルズ コーポレーション Local delivery of nucleic acid compounds
US10994025B2 (en) 2017-05-12 2021-05-04 Massachusetts Institute Of Technology Argonaute protein-double stranded RNA complexes and uses related thereto
WO2019055460A1 (en) 2017-09-13 2019-03-21 The Children's Medical Center Corporation Compositions and methods for treating transposon associated diseases
US11555189B2 (en) 2017-10-18 2023-01-17 Sarepta Therapeutics, Inc. Antisense oligomer compounds
KR101915949B1 (en) 2018-01-09 2018-11-07 주식회사 쎌바이오텍 Gene expression cassette and expression vector comprising the same
AR117409A1 (en) 2018-03-29 2021-08-04 Oxitec Ltd SELF-LIMITING NIGHTS
EP3772928B1 (en) 2018-04-06 2025-02-26 Children's Medical Center Corporation Compositions and methods for somatic cell reprogramming and modulating imprinting
JP7539161B2 (en) 2018-08-10 2024-08-23 ユーティレックス カンパニー リミテッド Chimeric antigen receptors that bind to HLA-DR and CAR-T cells
US20210324409A1 (en) 2018-08-14 2021-10-21 Oxitec Limited Self-Selecting Sterile Male Arthropods
AU2019406452B2 (en) 2018-12-21 2021-09-16 Ose Immunotherapeutics Humanized anti-human-PD-1 antibody
CN113573782B (en) 2018-12-21 2025-12-16 Ose免疫疗法公司 Bifunctional molecules directed against human PD-1
WO2020127377A1 (en) 2018-12-21 2020-06-25 Ose Immunotherapeutics Bifunctional anti-pd-1/il-7 molecule
US20220056135A1 (en) 2018-12-21 2022-02-24 Ose Immunotherapeutics Bifunctional anti-pd-1/sirpa molecule
WO2020165374A1 (en) 2019-02-14 2020-08-20 Ose Immunotherapeutics Bifunctional molecule comprising il-15ra
BR112021017770A2 (en) 2019-03-08 2021-11-16 Obsidian Therapeutics Inc CD40L Compositions and Methods for Adjustable Regulation
CA3155669A1 (en) 2019-09-27 2021-04-01 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
EP3835421A1 (en) 2019-12-11 2021-06-16 Consejo Superior de Investigaciones Científicas (CSIC) Vectors for tissue specific transcriptomics
AU2021205416B2 (en) 2020-01-08 2026-08-06 Obsidian Therapeutics, Inc. Compositions and methods for tunable regulation of transcription
EP4107268A4 (en) 2020-02-19 2024-03-27 Donaldson Company, Inc. AAV-BINDING POLYPEPTIDES WITH PURIFICATION Matrices and Methods of Using Them
US12692483B2 (en) 2020-02-19 2026-07-28 Donaldson Company, Inc. Protein-based purification matrices and methods of using the same
WO2021174742A1 (en) 2020-03-06 2021-09-10 生物岛实验室 Animal preparation method
JP2023549112A (en) 2020-11-05 2023-11-22 ネオイミューンテック， インコーポレイテッド How to treat tumors with a combination of IL-7 protein and nucleotide vaccines
EP4019539A1 (en) 2020-12-22 2022-06-29 Consejo Superior de Investigaciones Científicas (CSIC) Recombinant bacterium and uses thereof
WO2022204185A1 (en) 2021-03-22 2022-09-29 The University Of North Carolina At Chapel Hill Modified peptidomimetics and methods of use
AU2022261124A1 (en) 2021-04-22 2023-10-05 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating cancer
WO2025166032A1 (en) 2024-02-01 2025-08-07 Oxitec Limited Self-limiting, sex-specific transgenes and methods of use

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522750A (en) * 1984-02-21 1985-06-11 Eli Lilly And Company Cytotoxic compositions of transferrin coupled to vinca alkaloids
IN165717B (en) * 1986-08-07 1989-12-23 Battelle Memorial Institute
EP0273085A1 (en) * 1986-12-29 1988-07-06 IntraCel Corporation A method for internalizing nucleic acids into eukaryotic cells
US5166320A (en) * 1987-04-22 1992-11-24 University Of Connecticut Carrier system and method for the introduction of genes into mammalian cells
US5354844A (en) * 1989-03-16 1994-10-11 Boehringer Ingelheim International Gmbh Protein-polycation conjugates
NZ244306A (en) * 1991-09-30 1995-07-26 Boehringer Ingelheim Int Composition for introducing nucleic acid complexes into eucaryotic cells, complex containing nucleic acid and endosomolytic agent, peptide with endosomolytic domain and nucleic acid binding domain and preparation
US5521291A (en) * 1991-09-30 1996-05-28 Boehringer Ingelheim International, Gmbh Conjugates for introducing nucleic acid into higher eucaryotic cells

Also Published As

Publication number Publication date
AU5137290A (en) 1990-09-20
FI105485B (en) 2000-08-31
JP3138461B2 (en) 2001-02-26
ES2148136T3 (en) 2000-10-16
DE59010910D1 (en) 2000-09-07
KR900013980A (en) 1990-10-22
ZA901974B (en) 1991-11-27
NZ232918A (en) 1997-07-27
US5354844A (en) 1994-10-11
AU637085B2 (en) 1993-05-20
HUT53921A (en) 1990-12-28
HU211944A9 (en) 1996-01-29
PT93441B (en) 1997-01-31
CA2012311C (en) 2003-06-24
US5792645A (en) 1998-08-11
DD297842A5 (en) 1992-01-23
RU2113485C1 (en) 1998-06-20
KR0178022B1 (en) 1999-03-20
CA2012311A1 (en) 1990-09-16
NO901214D0 (en) 1990-03-15
RU2098487C1 (en) 1997-12-10
EP0388758B1 (en) 2000-08-02
HU218716B (en) 2000-11-28
EP0388758A1 (en) 1990-09-26
IL93755A0 (en) 1990-12-23
JPH03200800A (en) 1991-09-02
FI901297A0 (en) 1990-03-15
NO901214L (en) 1990-09-17
NO301932B1 (en) 1997-12-29
HU901583D0 (en) 1990-06-28
ATE195144T1 (en) 2000-08-15
GR3034717T3 (en) 2001-01-31
IL93755A (en) 1995-12-31
DK0388758T3 (en) 2000-11-13

Similar Documents

Publication Publication Date Title
AU637085B2 (en) New transferrin-polycation conjugates
DE69331946T2 (en) nucleozymes
Thomson et al. Activity of hammerhead ribozymes containing nonnucleotidic linkers
DE69125374T2 (en) ENDONUCLEASES
PT1210357E (en) Oligonucleotide n3`-p5` thiophosphoramidates: their synthesis and use
ES2183133T3 (en) LIPID COMPOSITIONS.
DE60028367D1 (en) OLIGONUCLEOTIDES CONTAINING AN ANTISENSE SEQUENCE STABILIZED BY A SEUCIDARY STRUCTURE AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEY
Furneaux et al. Isolation and characterization of two fractions from HeLa cells required for mRNA splicing in vitro.
CA2294709A1 (en) Compositions and methods for enhancing delivery of therapeutic agents to cells
Lornitzo et al. Subunits of fatty acid synthetase complexes. Enzymatic activities and properties of the half-molecular weight nonidentical subunits of pigeon liver fatty acid synthetase.
Harris et al. Differential effects of 3'-deoxy nucleosides on RNA synthesis in cotton cotyledons
Winkler et al. 2′‐O‐Lysylaminohexyl Oligonucleotides: Modifications for Antisense and siRNA
WO1994012518A3 (en) Reagent for coupling various substances to nucleic acids, and a method of preparing the reagent
Teas et al. The Enzymatic Synthesis of RUBBER1
Kanehisa et al. Partial specificity of low-molecular-weight RNA that stimulates RNA synthesis in various tissues
Hirose et al. GTP induces knotting, catenation, and relaxation of DNA by stoichiometric amounts of DNA topoisomerase II from Bombyx mori and HeLa cells.
Ittel et al. Heterogeneity of 32PO3− 4 incorporation in αPO3− 4 of free rat liver nucleotides
AU8818398A (en) Conjugates of dna interacting groups with steroid hormones for use as nucleic acid transfection agent
Fennell et al. Use of chromosomal translocations with in situ DNA hybridisation to confirm localisation of human 5S ribosomal RNA genes
HAMAZAKI Effect of adenosine 3', 5'-monophosphate on thymidine kinase in tumor cells
WO1997045547A3 (en) Localised cell death in plants
GP The structure of the RNA binding site of ribosomal proteins SS and S15. Reinhold Miller, Roger A. Garrett, and Harry F. Noller
Player et al. Methods for the Characterization of Phosphatase-Stabilized 2− 5A-Antisense Chimeras
Walker et al. Nucleic Acids-;: 0
Ait et al. Synthesis of 2-Deoxy-4-thio-D-ribofuranose and Its 3-Azido Analogue from L-Arabinose; Intermediates in the Synthesis of 4′-Thiodeoxynucleosides

Legal Events

Date Code Title Description
FG3A Patent granted, date of granting

Effective date: 19961015

MM4A Annulment/lapse due to non-payment of fees, searched and examined patent

Free format text: MAXIMUM VALIDITY LIMIT REACHED

Effective date: 20111017